Submitted by novartiscom2341 in business
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep
Submitted by novartiscom2341 in business
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS
Submitted by novartiscom2341 in business
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53
Submitted by novartiscom2341 in business
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53
Submitted by novartiscom2341 in business
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53
Submitted by novartiscom2341 in business
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53
Submitted by novartiscom2341 in business
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53
Submitted by novartiscom2341 in business
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of
Submitted by novartiscom2341 in business
Ad hoc announcement pursuant to Art. 53 LRFull year (continuing operations2) Ad hoc announcement pursuant
Submitted by novartiscom2341 in business
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an